Surgical Outcomes of Differentiated Thyroid Cancer at Stages T3b-T4N0M0 at Hanoi Medical University Hospital
Main Article Content
Abstract
This study aimed to evaluate the clinical and paraclinical characteristics, as well as surgical outcomes, of differentiated thyroid cancer (DTC) at stages T3b–T4N0M0. A descriptive study was conducted on 184 patients diagnosed with DTC at the aforementioned stages patients underwent surgery at Hanoi Medical University Hospital from January 2022 to March 2026. The mean age was 51.7 ± 12.5 years old, with a female-to-male ratio of 6.4:1. Tumor capsular invasion detected by ultrasound was observed in 11.4% of cases. Tumor invasion rates into the strap muscles, trachea, and recurrent laryngeal nerve were 84.8%, 9.2%, and 5.4%, respectively, with one patient (0.6%) showing simultaneous invasion of both the recurrent laryngeal nerve and the esophagus. The proportions of R0, R1, and R2 resections were 84.8%, 15.2%, and 0%, respectively. The rate of occult lymph node metastasis was 40.2%. Postoperative complications included transient hypocalcemia (manifested as extremity tetany) in 9.8%, hoarseness in 3.8%, and bleeding, infection, and chyle leak each in 0.5% of cases. No complication persisted beyond one month of treatment. These findings indicate that surgical management of T3b–T4N0M0 differentiated thyroid cancer achieves a high rate of complete resection with low complication rates, with all complications being transient.
Article Details
Keywords
Surgical treatment for locally advanced thyroid cancer, occult lymph node metastasis in thyroid cancer, differentiated thyroid cancer
References
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2): 87-108. doi:10.3322/caac.21262.
3. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-263. doi:10.3322/caac.21834.
4. Zhou P, Tian S, Li J, et al. Paradoxes in thyroid carcinoma treatment: analysis of the SEER database 2010-2013. Oncotarget. 2016; 8(1): 345-353. doi:10.18632/oncotarget.13395.
5. Chen L, Wu YH, Lee CH, Chen HA, Loh EW, Tam KW. Prophylactic Central Neck Dissection for Papillary Thyroid Carcinoma with Clinically Uninvolved Central Neck Lymph Nodes: A Systematic Review and Meta-analysis. World J Surg. 2018; 42(9): 1. doi:10.1007/s00268-018-4547-4.
6. Liu Z, Huang Y, Chen S, et al. Minimal extrathyroidal extension affects the prognosis of differentiated thyroid cancer: Is there a need for change in the AJCC classification system? PLOS ONE. 2019; 14(6): e0218171. doi:10.1371/journal.pone.0218171.
7. Bortz MD, Kuchta K, Winchester DJ, Prinz RA, Moo-Young TA. Extrathyroidal extension predicts negative clinical outcomes in papillary thyroid cancer. Surgery. 2021; 169(1): 2-6. doi:10.1016/j.surg.2020.04.003.
8. Kim H, Kim JA, Son EJ, et al. Preoperative prediction of the extrathyroidal extension of papillary thyroid carcinoma with ultrasonography versus MRI: A retrospective cohort study. Int J Surg. 2014; 12(5): 544-548. doi:10.1016/j.ijsu.2014.03.003.
9. Extrathyroidal Extension in Papillary Thyroid Cancer Could be Predicted Through Preoperative Sonography. Int J Thyroidol. 2024; 17(2): 266-271. doi:10.11106/ijt.2024.17.2.266.
10. Nguyễn Thị Thu Nhung, Lê Văn Quảng, Nguyễn Xuân Hậu. Đánh giá tình trạng di căn hạch tiềm ẩn trong ung thư biểu mô tuyến giáp giai đoạn sớm. Tạp chí Y học Việt Nam. Published online 2019.
11. Chung SR, Baek JH, Choi YJ, et al. Sonographic Assessment of the Extent of Extrathyroidal Extension in Thyroid Cancer. Korean J Radiol. 2020; 21(10): 1187-1195. doi:10.3348/kjr.2019.0983.
12. Wang LY, Nixon IJ, Patel SG, et al. Operative management of locally advanced, differentiated thyroid cancer. Surgery. 2016; 160(3): 738-746. doi:10.1016/j.surg.2016.04.027.
13. Chiew YEW, Yang YT, Chi SY, et al. Prognostic factors and treatment responses among patients with gross residual disease in differentiated thyroid cancer. J Chin Med Assoc JCMA. 2024; 87(6): 602-608. doi:10.1097/JCMA.0000000000001095.
14. Jeong SY, Lee SW, Kim WW, et al. Clinical outcomes of patients with T4 or N1b well-differentiated thyroid cancer after different strategies of adjuvant radioiodine therapy. Sci Rep. 2019; 9(1): 5570. doi:10.1038/s41598-019-42083-3.
15. Fei Y, Wang B, Yao X, Wu J. Factors associated with occult lateral lymph node metastases in patients with clinically lymph node negative papillary thyroid carcinoma: a systematic review and meta-analysis. Front Endocrinol. 2024; 15: 1353923. doi:10.3389/fendo.2024.1353923.